Cerus Co. (NASDAQ:CERS – Get Rating)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $3.82, but opened at $3.70. Cerus shares last traded at $3.93, with a volume of 7,795 shares.
Analysts Set New Price Targets
A number of research firms have recently commented on CERS. StockNews.com began coverage on shares of Cerus in a research note on Wednesday, October 12th. They set a “hold” rating for the company. BTIG Research reduced their price objective on shares of Cerus to $6.00 in a research note on Tuesday, November 15th.
Cerus Stock Performance
The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.44 and a current ratio of 1.73. The stock’s fifty day moving average price is $3.68 and its 200-day moving average price is $4.55. The company has a market capitalization of $693.71 million, a P/E ratio of -17.77 and a beta of 1.11.
Institutional Investors Weigh In On Cerus
A number of institutional investors and hedge funds have recently modified their holdings of the company. Ensign Peak Advisors Inc bought a new position in Cerus in the 3rd quarter valued at about $39,000. Capital Impact Advisors LLC bought a new position in Cerus in the 3rd quarter valued at about $49,000. Prelude Capital Management LLC raised its holdings in Cerus by 28.1% in the 3rd quarter. Prelude Capital Management LLC now owns 20,264 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 4,445 shares during the period. Lazard Asset Management LLC raised its holdings in Cerus by 59.2% in the 1st quarter. Lazard Asset Management LLC now owns 13,453 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 5,004 shares during the period. Finally, Baker Tilly Wealth Management LLC bought a new position in Cerus in the 2nd quarter valued at about $74,000. 84.72% of the stock is owned by institutional investors.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
- Get a free copy of the StockNews.com research report on Cerus (CERS)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.